Loading your page…
Frontiers in microbiology
By Talebzadeh S and Saris PEJ.
Inroduction: Emerging evidence links fecal Desulfovibrio (DSV) abundance with Parkinson's disease (PD) severity. While probiotics may relieve symptoms, their direct effects on DSV remain unexplored.
Ward brings these articles into the same app as your cards and questions. One free account for Ward, Suture, Osler and Prognia.
This study evaluated the inhibitory potential of 32 probiotic and potential probiotic strains against three DSV strains isolated from three individual PD patients. Antimicrobial activity was quantified using agar well diffusion and microplate assays, and the operational minimum inhibitory con centration (MIC₉₀) was determined based on the total crude dry matter content of cell-free supernatants (CFS).
All tested lactic acid bacteria (LAB) strains, except Limosilactobacillus reuteri Hambi410, inhibited DSV. Quantitative micro assay results showed that Lacticaseibacillus rhamnosus LGG exhibited the highest inhibition (up to 44.82% ± 8.31%) after neutralization and catalase treatment. Among the eight tested Bifidobacterium strains, Bifidobacterium bifidum CUL-17 and Bifidobacterium longum E-96664 exhibited inhibitory effects comparable to those observed in LAB. The MIC₉₀ values revealed that Lactobacillus acidophilus Hambi1448 and Lactiplantibacillus plantarum E98 were the most potent, with MIC₉₀ values ranging from 25.2 to 29.8 mg/mL. Spearman's correlation confirmed a significant inverse relationship between initial pH and inhibition zones (p < 0.001). Crucially, analysis of covariance (ANCOVA) demonstrated that strain specific inhibitory variations remained highly significant (p < 0.005) after statistically controlling for the confounding effect of acidification, which is consistent with the involvement of non-acidic bioactive metabolites. Probiotic Bacillus strains showed no direct inhibition but are discussed for their role in alleviating PD-related constipation.
These findings demonstrate that specific probiotics can target PD-derived DSV, offering a novel strategy for microbiome-based PD management.
Published in Frontiers in microbiology. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
